顶尖药企竞相推出减重口服药

环球市场播报03-06

全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP‑1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　以下是竞相研发口服减重药、希望在这一高利润市场占据一席之地的部分...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2617635561?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-06 22:16","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2617635561","market":"sg","top_or_hot":-1,"title":"顶尖药企竞相推出减重口服药","media":"环球市场播报","content":"<div>\n<p>全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。\n　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。\n　　诺和诺德成为首家推出口服 GLP‑1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。\n　　以下是竞相研发口服减重药、希望在这一高利润市场占据一席之地的部分...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>顶尖药企竞相推出减重口服药</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n顶尖药企竞相推出减重口服药\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-06 22:16 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。\n　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。\n　　诺和诺德成为首家推出口服 GLP‑1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。\n　　以下是竞相研发口服减重药、希望在这一高利润市场占据一席之地的部分...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999002232.USD","symbol_name":"Allianz Global High Payout USD","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-06/doc-inhqanka2342553.shtml","article_id":"2617635561","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617635561","pubTimestamp":1772806560,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。　　诺和诺德成为首家推出口服 GLP1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。　　中国歌礼制药的在研口服 GLP1 药物ASC30，在美国二期临床试验中最高减重7.7%。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999002232.USD":"Allianz Global High Payout USD","BK4588":"碎股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","BK4007":"制药","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LLY":"礼来","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","NVO":"诺和诺德","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","000963":"华东医药","BK1161":"生物科技","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK4581":"高盛持仓","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","VKTX":"Viking Therapeutics, Inc.","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","PFE":"辉瑞","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0122379950.USD":"贝莱德世界健康科学A2","BK4550":"红杉资本持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK4533":"AQR资本管理(全球第二大对冲基金)","BK1583":"高瓴概念","MRK":"默沙东","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","01801":"信达生物","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","RHHBY":"罗氏控股","BK4568":"美国抗疫概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK1589":"北水核心资产","AZN":"阿斯利康"},"translate_title":"Top pharmaceutical companies compete to launch weight-loss oral drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1.92,"RHHBY":1.83,"VKTX":1.82,"000963":1.8,"AZN":1.84,"MRK":1.85,"01801":1.81,"PFE":1.88,"LLY":1.93},"content_text":"全球减重药物市场正进入新阶段，推动因素包括口服剂型上市、仿制药竞品即将到来，以及礼来、诺和诺德旗下重磅产品在美国降价。\n　　这一快速变化的格局，促使华尔街重新审视未来十年减重药市场规模将达 1500 亿美元的长期预测。\n　　诺和诺德成为首家推出口服 GLP‑1 减重药的企业，这家丹麦药企在快速演变的减重治疗市场中获得了竞争优势。\n　　以下是竞相研发口服减重药、希望在这一高利润市场占据一席之地的部分企业：\n　　礼来（Eli Lilly）\n　　该公司的每日一次非肽类口服 GLP‑1 受体激动剂 Orforglipron，在三期临床试验中，最高剂量组可使非糖尿病超重成年人在 72 周内减重 12.4%。\n　　另一项研究显示，从礼来注射剂 Zepbound 及竞品诺和诺德 Wegovy 换用口服 Orforglipron 后，可帮助患者维持减重效果。礼来计划最早于今年第二季度在美国推出 Orforglipron，尚待美国食品药品监督管理局（FDA）批准。\n　　结构治疗公司（Structure Therapeutics）\n　　正在研发口服非肽类 GLP‑1 受体激动剂GSBR‑1290。\n　　在一项 230 人参与的二期临床试验中，服药 36 周后最高减重幅度达11.3%。公司计划在 2026 年年中与 FDA 召开会议后，启动该药物的三期临床。\n　　默沙东（Merck）\n　　与翰森制药合作，准备对口服小分子 GLP‑1 受体激动剂HS‑10535开展早期临床试验，目前该药物正在进行实验室研究。\n　　阿斯利康（AstraZeneca）\n　　与 Eccogene 公司共同推进每日一次口服 GLP‑1 受体激动剂ECC5004。\n　　早期临床试验显示出积极的减重信号与良好安全性，二期临床试验将由阿斯利康主导推进。\n　　罗氏（Roche）\n　　在收购 Carmot Therapeutics 后，罗氏正在开发口服 GLP‑1 受体激动剂CT‑966。\n　　去年一项早期临床试验显示，在非糖尿病肥胖患者中，用药四周后较安慰剂组平均减重6.1%。\n　　维京治疗公司（Viking Therapeutics）\n　　正在开发VK2735口服制剂，可同时靶向调节人体代谢的 GLP‑1 与 GIP 两种激素。\n　　二期临床试验中，这款在研口服减重药帮助患者减重12.2%，未达到华尔街预期上限 15%。\n　　辉瑞（Pfizer）\n　　在与诺和诺德激烈竞购后，辉瑞以 100 亿美元收购减重药研发公司 Metsera，正式进入高利润减重药市场。\n　　通过该交易，辉瑞获得两款长效口服 GLP‑1 药物，目前正在进行临床前试验。辉瑞与中国合作伙伴信诺维医药的每周一次减重注射剂先为唯已在中国获批，对诺和诺德、礼来及信达生物的已上市产品构成压力。辉瑞曾开发每日两次口服 GLP‑1 药物danuglipron，但因二期临床数据显示耐受性较差而终止研发。\n　　信达生物（Innovent Biologics）\n　　中国信达生物的口服 GLP‑1 减重药IBI3032，正在美国和中国开展早期临床试验。\n　　华东医药（HuaDong Pharmaceutical）\n　　中国华东医药的在研口服减重药HDM1002，在中国超重或肥胖受试者的早期研究中，最高减重幅度达6.8%。\n　　歌礼制药（Ascletis Pharma）\n　　中国歌礼制药的在研口服 GLP‑1 药物ASC30，在美国二期临床试验中最高减重7.7%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郭明煜","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617635561","isCrawlerRequest":true}